NEWELLINK

Pharmaceuticals, namely agents to treat cancer, autoimmunity, chronic viral infections, and other diseases characterized by abnormal cellular proliferation, and to improve tissue regeneration, wound healing, and transplantation

diagnostic kits comprising reagents for determining the metabolic pathway used by tumors

licensing of intellectual property